Volume | 4,833 |
|
|||||
News | - | ||||||
Day High | 5.33 | Low High |
|||||
Day Low | 5.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.33 | 5.00 | 5.33 | 5.20 | 5.35 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
129 | 4,833 | $ 5.10 | $ 24,650 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:21:45 | 88 | $ 5.00 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
19.43M | 3.74M | - | 583k | -14.29M | -3.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.59 | 5.88 | 5.00 | 5.25 | 7,329 | -0.39 | -6.98% |
1 Month | 6.64 | 6.73 | 5.00 | 5.94 | 7,253 | -1.44 | -21.69% |
3 Months | 6.07 | 8.8465 | 5.00 | 6.66 | 34,110 | -0.87 | -14.33% |
6 Months | 3.94 | 8.8465 | 3.35 | 6.15 | 21,841 | 1.26 | 31.98% |
1 Year | 3.78 | 8.8465 | 2.78 | 4.70 | 26,023 | 1.42 | 37.57% |
3 Years | 92.80 | 156.00 | 2.78 | 80.00 | 620,952 | -87.60 | -94.40% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.71 | 561,869 | -304.00 | -98.32% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |